Abstract: An expandable intervertebral fusion cage that includes an inferior baseplate and a superior baseplate, an insert rotatably received between the inferior and superior baseplates, and a guide pin coupled to the inferior and superior baseplates for facilitating the rotation of the insert. The insert includes a pair of protuberances, each of which are releasably engageable with a corresponding lock groove formed within the inferior and superior baseplates. When said insert is rotated relative to the guide pin, the protuberances engage the lock grooves, and the inferior and superior baseplates expand from a collapsed position, in which said inferior and superior baseplates are juxtaposed with one another, and an expanded position, in which said inferior and superior baseplates are diverged away from one another. Tabs formed on the superior baseplate continuously engage slots formed within the inferior baseplate when the baseplates expand from their collapsed position to their expanded position.

Abstract: An expandable intervertebral fusion cage that includes an inferior baseplate and a superior baseplate, an insert rotatbly received between the inferior and superior baseplates, and a guide pin coupled to the inferior and superior baseplates for facilitating the rotation of the insert. The insert includes a pair of protuberances, each of which are releasably engageable with a corresponding lock groove formed within the inferior and superior baseplates. When said insert is rotated relative to the guide pin, the protuberances engage the lock grooves, and the inferior and superior baseplates expand from a collapsed position, in which said inferior and superior baseplates are juxtaposed with one another, and an expanded position, in which said inferior and superior baseplates are diverged away from one another. As a result, the cage distracts in parallel.

Abstract: This invention provides a method for inhibiting angiogenesis in mammals. A pharmaceutically acceptable formulation containing a compound of the formula ##STR1## where X.sub.1 X.sub.2 and X.sub.3 are H, C1, or F and X.sub.3 must be H if the substituent of R.sub.1 is .alpha.OH;R.sup.1 is chosen from the group consisting of hydroxyl and hydrogen;R.sub.2 is chosen from the group of alkyloxy or thioalkyls wherein said alkyls have less than 5 carbon atomsR.sub.3 is H or an alkyl having less than 6 carbon atoms, is administered to the mammal having undesirable angiogenesis.The wavy line at C-16 refers to either .alpha. or .beta..